Erste Asset Management GmbH Grows Stock Position in Xencor, Inc. $XNCR

Erste Asset Management GmbH increased its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 26.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 480,200 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Xencor were worth $7,347,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Xencor in the 4th quarter worth about $175,000. Intech Investment Management LLC raised its holdings in shares of Xencor by 138.6% in the 4th quarter. Intech Investment Management LLC now owns 70,612 shares of the biopharmaceutical company’s stock worth $1,081,000 after purchasing an additional 41,015 shares during the period. Geode Capital Management LLC raised its holdings in shares of Xencor by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 1,752,918 shares of the biopharmaceutical company’s stock worth $26,842,000 after purchasing an additional 24,093 shares during the period. Legal & General Group Plc raised its holdings in shares of Xencor by 2.8% in the 4th quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock worth $20,027,000 after purchasing an additional 35,088 shares during the period. Finally, Jefferies Financial Group Inc. raised its holdings in shares of Xencor by 620.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after purchasing an additional 620,440 shares during the period.

Analyst Upgrades and Downgrades

XNCR has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. raised their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Wall Street Zen downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Zacks Research downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Finally, Barclays raised their price objective on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $24.50.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $11.41 on Tuesday. The company has a market cap of $845.94 million, a P/E ratio of -4.98 and a beta of 0.92. Xencor, Inc. has a one year low of $6.92 and a one year high of $18.69. The business’s 50-day simple moving average is $12.11 and its 200 day simple moving average is $13.20.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The company had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The business’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.66) earnings per share. Analysts predict that Xencor, Inc. will post -3.84 earnings per share for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.